BSHI programme v 3

P15: An Evaluation of Rapid HLA Typing Technologies for Deceased Organ Donor Typing
Shahram Hemmatpour¹, Jennifer Gauss¹, Thahminna Khan¹, Diane Irving², Deborah Sage¹
1 NHS Blood and Transplant, Tooting, London, UK
2 NHS Blood and Transplant, UK
An evaluation of technologies available for rapid HLA typing of deceased organ donors was undertaken in
order to establish a common approach across NHSBT H&I laboratories. The HLA typing platforms were
evaluated against the following criteria:

i. Rapid HLA typing (no more than 3 hours after DNA extraction, to the availability of an interpreted
result) combined with robust, flexible and intuitive technology;

ii. Allow for multiple samples to be process at staggered start times with no impact on turnaround
time;

iii. HLA typing results must be compliant with the minimum HLA typing requirements for recipients
and donors (NHSBT-ODT);

iv. High levels of automation and low levels of manual intervention;
v. A low incidence of unresolved HLA ambiguities;
vi. The ability to include electronic transfer of results from the analyser to the LIMS system
Seven HLA typing platforms were evaluated. Technologies included Luminex HLA typing, real time PCR-SSP,
reverse PCR-SSOP and PCR-SSP. A total of 11 HLA types were performed for each platform designed to test
reproducibility of results and robustness of the typing system.
Every stage of the typing process was timed for each platform, in order to establish the impact of
multiple samples at staggered start times.
A reproducible HLA type and assay robustness was demonstrated by each platform. Four platforms did not
meet the required 3 hour turnaround time however when combining the requirement to allow for multiple
samples at staggered start times, only the real time PCR-SSP platform was able to maintain the required
turnaround time.

P16: Validation of Flow Cytometric CD34+ Cell Enumeration Following the ISHAGE Protocol
Prior to Haematopoietic Stem Cell Donation
Shannon Brooks¹, Steven Jervis¹, Natalia Diaz Burlinson¹, Kay Poulton¹

1 Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK

Page 51 of 84

Background Flow Cytometric CD34⁺ enumera�on is used to quan�fy haematopoie�c progenitor and stem
cells prior to transplant in order to ensure an optimal yield and predict engraftment. The ISHAGE protocol
was developed to minimise inter‐laboratory variation and is the most popular CD34⁺ enumera�on protocol
used throughout the UK. Our aim was to successfully validate this method for routine use.

Method 29 samples of known CD34⁺  absolute  counts  and  viability  were  tested  using  Beckman  Coulter
stem-kit™ reagents following the single-platform ISHAGE protocol. 18 samples were apheresis product, four
were peripheral blood and seven were bone marrow. The absolute CD34⁺ count was calculated using a known
concentra�on of fluorospheres as part of the kit. In addition, four UK NEQAS samples were tested.

Results 16 samples had satisfactory CD34⁺ absolute counts with a mean CV of 8%. Seven samples were
excluded because of unsatisfactory cell viability due to a significant time delay in receiving the samples post
collection. The remaining six samples were deemed unsatisfactory due to technical errors which were
overcome with further training and experience. Of the four NEQAS results three had satisfactory counts, one
did not produce duplicates within 10% of the mean. Overall, there was concordance of 73.1% (19/26).

Conclusion The  NEQAS  results  and  concordant  absolute  CD34⁺  counts  provide  good  evidence  that  this
protocol is successful. The results however demonstrate the necessity for good sample viability and adequate
storage, and importantly, that the addition of the fluorospheres is performed accurately for a reliable CD34⁺
absolute count.

P17: Using Sequence-Specific Oligonucleotide (SSO) for Deceased Donor HLA Typing, A
Single Centre Experience

Mazen Mabrok¹, Kim Boswijk¹, Bryan Sean Carey¹, Anthony Poles¹

1 H& I laboratory, Derriford Hospital, Plymouth, UK

The majority of UK laboratories continue to perform HLA typing on call using polymerase chain reaction
sequence specific primer (PCR-SSP) to perform deceased donor types, although non-urgent HLA typing is
performed by sequence specific oligonucleotide (PCR-SSO). The Royal College of Pathologists standards for
HLA typing on call states that 80% of donors should be typed within 8 hours of phlebotomy so any
methodology that can reduce laboratory time is of benefit.

Following the failure of a commercial PCR-SSP kit to reliably resolve HLA-DQ3 splits, the H&I laboratory in
Plymouth evaluated Luminex based kits (One Lambda LAB Type®) to support HLA typing of deceased donor
kidneys in June 2014.

The laboratory now performs deceased donor HLA typing using HLA READY GENE PCR-SSP (Inno-train
Diagnostik GmbH) and One Lambda PCR-SSO. This has improved the performance of the laboratory by
reducing the average laboratory time from five hours and fifty five minutes for simultaneous use of two
PCR-SSP kits to five hours and twenty seven minutes when using both PCR-SSP and PCR-SSO.

Page 52 of 84

Using PCR-SSO provided a 14% reduction in cost compared to the PCR-SSP kit it replaced, and reduced the
number of kits that require batch verification and monitoring, thereby saving additional laboratory time.
SSO typing also provides additional HLA-DQA1 and DPA1 typing information and simplify the analysis by
allowing automatic exclusion of rare allele combinations when the common well defined (CWD) filter is used.
PCR-SSO has proven to be cheaper and faster than the combined use of two PCR-SSP kits and, once trained,
staffs have commented that the process is less demanding.

Molecular and Population Genetics

P18: Genetic Analysis in Glanzmann's Thrombasthenia: Identification Of Seven Novel
Mutations
Anthony Poles¹, Geoffrey Lucas¹, Elizabeth Wroe¹, Leigh Keen¹

1 NHSBT – Bristol, Bristol, UK

The clinical diagnosis of Glanzmann’s thrombasthenia (GT) can be confirmed by a reduction or absence of
expression of the GPIIb/IIIa complex as determined by platelet immunophenotyping. Sequencing of the
relevant genes can also aid diagnosis and when combined with clinical presentation and agonist testing
provides insights to the function of GPIIb/IIIa.
Direct sequencing of the coding region and intron/exon boundaries of the ITGB3 and ITGA2B genes was
performed on eleven GT patients.
Seven novel mutations were identified in five patients. One patient possessed a novel frameshift
mutation that resulted in a premature stop codon in ITGA2B
(NM_000419.3:c559delG/NP_000410:p.V187Wfs). Two patients possessed missense mutations in ITGB3
that resulted in both G319E and T456P substitutions. One patient possessed a novel intron mutation in
ITGB3 (NG_008332.2:g.58805C>T), and a missense mutation in ITGA2B (E698D). The remaining patient
possessed two novel missense mutations in ITGA2B that resulted in Y268N and V359M substitutions.
Six patients had previously described mutations; two possessed an ITGB3 mutation (L143W), one had a
mutation in ITGB3 (D145N) and one had a mutation in ITGA2B (A989T). In a familial study, a mother and
daughter both possessed an ITGB3 mutation (P186L) but the mother had two additional mutations in ITGB3
(R750Q) and ITGA2B (V649L).
The advantage of gene analysis is that a diagnosis of GT can be confirmed in the absence of platelets for
GPIIb/IIIa estimation or if the patient has received recent platelet transfusions. In addition, sequencing may
identify mutations in spite of apparently normal levels of GPIIb/IIIa on platelets.

Page 53 of 84

Other Aspects of H&I

P19: {AT}toolset - Addressing the Bioinformatics Challenges of High Throughput HLA Typing
Using SMRT® Sequencing

Robinson James¹, Cristina Guijarro¹, Gayle Leen², Jeremy E. Stein², Neema P. Mayor¹, Katy Latham², J.
Alejandro Madrigal¹, Steven G. E. Marsh¹
1 Anthony Nolan Research Institute & UCL Cancer Institute, London, UK
2 Anthony Nolan Research Institute, London, UK

The introduction of Pacific Biosciences’ Single Molecule Real Time (SMRT®) sequencing for HLA typing
enables sequencing of fully phased long reads, capable of spanning the full length of HLA class I and the
majority of class II. Processing a high volume of multiplexed samples on a high-throughput sequencing
platform produces very large data sets, known typically as “big data”, which create data storage,
computational and analysis challenges for existing bioinformatics platforms. In order to address these
challenges we have developed a software suite, {AT}toolset, to provide a fully automated analysis pipeline.
The software suite provides monitoring and data collection from the Pacific Biosciences’ RS II sequencer,
de-multiplexing of barcoded samples, consensus sequences generation, HLA typing assignment and lastly
performs quality control checks on the final results. The software is configured to handle the high volume
of data from multiple sequencers and developed to run on a single high specification Unix server, removing
the need for different servers or desktop machines at each stage of the process. Analysis can optimally
provide results for a single SMRT cell, containing material from 48 individuals for three genes, in under ninety
minutes of the raw data been made available. The pipeline, from loading the RS II machine to the output of
results, runs in the background without requiring any manual intervention thus reducing the opportunity
for human error. The software has been optimised for both accuracy and throughput. The development of
{AT}toolset has enabled high-throughput clinical typing of HLA within a registry setting.

P20: Five new HLA-A, B, DRB1, DQB1 alleles with synonymous mutations - A*01:01:65,
A*01:01:66, B*44:03:35, DRB1*15:01:30 and DQB1*02:01:24

Jane Street¹, Elaine Davies¹, Timothy Climer¹, Chris Darke¹

1 Welsh Transplantation and Immunogenetics Laboratory, Cardiff, UK

During routine HLA typing of blood donors, for the Welsh Bone Marrow Donor Registry, five new HLA
sequences exhibiting synonymous mutations were identified in UK Europeans.

HLA typing was initially performed by Histogenetics and subsequently confirmed by sequencing of exons
2, 3 and 4 for HLA-A, B, exon 2 for DRB1 and exons 2 and 3 for DQB1. These were: A*01:01:65 (cell
identification 71554) and A*01:01:66 (16328744) that both differ from A*01:01:01 by single substitutions
in exon 3 (576C>T, codon 168 and 573G>T,

Page 54 of 84

codon 167, respectively). Similarly, the following differ by single substitutions in exon 2: B*44:03:35 (74027)
differs from B*44:03:01:01 (256C>A, codon 62); DRB1*15:01:30 (10RZB4) differs from DRB1*15:01:01:01
(198C>T, codon 37) and DQB1*02:01:24 (48834) differs from DQB1*02:01:01 (351G>A,codon 85).
Serological typing, using 300 well-documented local antisera and 144 monoclonal antibodies (One Lambda
Inc.) showed that A*01:01:65, B*44:03:35, and DQB1*02:01:24 each encode a normal specificity (others
not tested).

Family studies indicated that the likely A*01:01:65-bearing haplotype is: A*01:01:65, B*07:02, C*07:02,
DRB1*14:01, DQB1*05:03.

The other new allele bearing haplotypes were predicted from allele frequency and linkage disequilibrium
estimates from local population genetics information as:

A*01:01:66, B*35:03, C*12:03, DRB1*15:01, DQB1*06:02; A*02:01, B*44:03:35, C*16:01, DRB1*07:01,
DQB1*02:01/02; A*25:01, B*18:01/17N, C*12:03, DRB1*15:01:30, DQB1*06:02 and A*01:01, B*08:01,
C*07:01/06, DRB1*03:01, DQB1*02:01:24.

These five novel alleles were identified in a sequence-based typed population of 32,530 subjects resident
in Wales and largely UK Europeans. This suggests that each has a maximum allele frequency 0.00002, and
a carriage frequency of 0.0031%, in our local normal blood donor population.

P21: A New HLA-DRB1*15 Allele - DRB1*15:112

Jane Street¹, Chris Harvey², Jayne Johnson³, Chris Darke²

1 Welsh Transplantation and Immunogenetics laboratory, Cardiff, UK
2 Welsh Transplantation and Immunogenetics Laboratory, Cardiff, UK
3 NHSBT Filton, Bristol, UK

During HLA typing, by Histogenetics, of donors for the Welsh Bone Marrow Donor Registry, a new
HLA-DRB1*15 allele was identified and named DRB1*15:112. We subsequently confirmed this sequence,
from our Sinhalese Shi Lankan donor (cell identification 16240383), which differs from DRB1*15:01:01:01
by a single base (282G>T) in exon 2, resulting in an amino acid substitution of K65N.

Serological typing using polyclonal, and monoclonal antibodies (One Lambda Inc.), of 16240383 gave the
expected HLA-A,B,C,DR,DQ assignments. However, one reliable monoclonal antibody (‘Butch DR15’) was
negative. Thus, ‘Butch DR15’ may be recognising an epitope involving 65K.

Nineteen epitopes possessed by DR15 and other DRB1/3/4/5 products in the ‘Epitope Registry’ are
within 15 Angstroms of 65 so could, with 65K, represent a further epitope. However, 65K is consensus
for DRB1 so these would not be DR15 unique.

Nonetheless, we identified several motifs that are unique to DRB1*15, comply with the 2- patch epitope
concept and involve 65K, e.g. 65K, 71A is possessed by most DR15 but not the DRB1*15:112 product.

Page 55 of 84

The donor’s type is HLA-A*01:01, A*33:03; B*15:02, B*58:01; C*03:02, C*08:01; DRB1*10:01, DRB1*15:112;
DQB1*05:01, DQB1*06:01. Removal of the recognised Asian haplotype A*33:03, B*58:01, C*03:02,
DRB1*10:01, DQB1*05:01 suggests that the DRB1*15:112-bearing haplotype is A*01:01, B*15:02, C*08:01,
DRB1*15:112, DQB1*06:01.

This allele was identified in a random sequence-based typed population of 32,530 subjects resident in Wales.
These are largely UK Europeans with Asian/British Asian representing just some 2% of the population. This
indicates a low precision DRB1*15:112 frequency of 0.00002 (carriage frequency 0.003%) in our local blood
donor population.

P22: Five New HLA-A, B, C, DQB1 Alleles with Nonsynonymous Mutations - A*11:241,
B*49:43, C*03:321, C*08:132 and DQB1*02:72

Jane Street¹, Elaine Davies², Chris Harvey², Chris Darke²
1 Welsh Transplantation and Immunogenetics laboratory, Cardiff, UK
2 Welsh Transplantation and Immunogenetics Laboratory, Cardiff, UK

During routine HLA typing of blood donors, for the Welsh Bone Marrow Donor Registry, five new HLA
sequences exhibiting nonsynonymous mutations were identified in UK Europeans. HLA typing was initially
performed by Histogenetics and subsequently confirmed by sequencing of exons 2, 3 and 4 for HLA-A, B,
C and exons 2 and 3 for DQB1.

All were WHO named in May 2016 and all differed from their closest sequence by a single nucleotide
substitution:

A*11:241 (cell identification 73936) differs from A*11:01:01:01 (215G>A, exon 2, R48Q); B*49:43
(16070844) differs from B*49:01:01 (362G>T, exon 3, R97M);

C*03:321 (15200434) differs from C*03:01:01 (234G>C, exon 2, Q54H);

C*08:132 (74324) differs from C*08:02:01:01 (587T>A exon 3, L172Q) and DQB1*02:72 (13381598)
differs from DQB1*02:01:01(185G>A exon 2, S30N).

Serological HLA-A, B, C, DR, DQ typing, using 300 well-documented local antisera, and 144 monoclonal
antibodies (One Lambda Inc.) showed that A*11:241 and C*08:132 each encode a normal serological
specificity (others not tested).

The new allele bearing haplotypes were predicted, where possible, from allele frequency and linkage
disequilibrium estimates from local population genetics information, and elsewhere as: A*11:241, B*35:01,
C*04:01, DRB1*04:07, DQB1*03:01;

A*02:05, B*49:43, C*07:01, DRB1*04:01, DQB1*03:01/DRB1*01:02, DQB1*05:01; A*01:01, B*55:01,
C*03:321, DRB1*04:07, DQB1*03:01;

A*03:01, B*14:01, C*08:132, DRB1*07:01, DQB1*02:02; A*02:01, B*58:01, C*07:18, DRB1*03:01,
DQB1*02:72.

Page 56 of 84

These five new alleles were identified in a sequence-based typed population of 32,530 subjects resident in
Wales and largely UK Europeans. This suggests that each has a maximum allele frequency of 0.00002, and
a carriage frequency of 0.0031%, in our local normal blood donor population.

P23: Correlation of Luminex Single Antigen Bead Assay and Renal Function For Post-
Transplant Monitoring

Mahendra Mishra¹, Tanya Shovlin¹, Ashley Meenagh¹, Aisling Courtney¹, Jeanie Martin¹

1 Belfast City Hospital, Belfast, UK

Background Single antigen bead assay (SAB) is often used for post-transplant monitoring at a frequency
determined by the sensitisation status of recipients.

Aim and Objectives This retrospective pilot study was performed to evaluate the usefulness of SAB assay
for post-transplant monitoring of allograft recipients, to correlate the MFI values with renal function and
examine the hierarchy if any of donor specific antibodies (DSA) contributing to allograft dysfunction.

Methods Data of 25 non-consecutive renal transplants was studied from laboratory records and DSA values
were correlated with renal parameters (urea and creatinine).

Results Living donors accounted for 60% of donations. The mean number of ABDR mismatches was
3.56 (0-6) and mean follow up period was 7.52 years (0.5 -30). Eight

recipients had no / insignificant cumulative DSA (SAB MFI < 1500) during the follow up period.

HLA-Class II DSA were more common of which anti DQB1 antibodies were most frequent (70%). Four patients
with high anti DQB1 antibodies had normal post-transplant graft function at 6 months- 3 years. HLA Class II
antibodies were detected in all recipients with suboptimal graft function, of which anti-DQB1 antibodies
were most common (70%).

Conclusions This study showed that SAB assay is useful for post-transplant monitoring. Secondly anti DQB1
antibodies are common and are likely to lead to suboptimal graft function after a variable period of being
detected.

P24: Three Atypical Null Alleles Identified in Deceased Solid Organ Transplant Donors Whilst
Performing HLA Typing On-Call

Zoe Thomas¹, Waseem Alvi-Ali¹, Jennifer Rawson¹, Luke Foster¹, David Briggs¹

1 NHS Blood and Transplant, Birmingham , UK

The definition of null alleles for determining HLA compatibility in solid organ transplantation is not considered
clinically significant. Although, DR51N and DR53N are listed in the ODT minimum typing requirements, they
do not form part of the National Kidney Allocation Scheme (NKAS) algorithm. Here we describe the detection
of three unusual HLA null alleles

Page 57 of 84

identified during emergency on-call deceased donor HLA typing using our ‘in-house’ null and supplementary
typing system which augments our commercial PCR-SSP assays.

HLA-DRB4*03:01N was identified on an HLA-DRB1*07-DQB1*02 bearing haplotype. Because the SSP
reactions detecting the expressed HLA-DRB4 allele were negative, further typing was performed on-call by
PCR-SSO (LIFECODES®), which failed to detect the presence of HLA-DRB4. Verification of the presence of
HLA- DRB4*03:01N in the absence of an expressed HLA-DRB4 variant allele was confirmed by the use of a
commercial high resolution HLA‐DRB4 PCR‐SSP assay (Olerup SSP®) and Real‐Time PCR assay (Linksēq™).

HLA-C*04:09N was detected on an HLA-B*44:03 bearing haplotype, with which it is commonly associated
(Pinto et al., Human Immunology 2004, 65 (2):181). Although the allele frequency of HLA-C*04:09N is 0.004,
as determined by local ten-year frequency data, this is the first time we have detected this null allele on-call.

Finally, the HLA-DRB4*01:03:01:02N allele was detected on an HLA-DRB1*09-DQB1*03:03 bearing
haplotype. This was unusual as HLA-DRB4*01:03:01:02N is commonly found on HLA- DRB1*07-DQB1*03:03
bearing haplotypes. HLA-DRB4*01:03:01:02N has a local allele frequency of 0.044 but this is the first
instance in which we have identified the allele in combination with HLA-DRB1*09.

Solid Organ Transplantation

P25: Lack of Correlation between SAB MFI and Flowcytometry Crossmatch in two Patients
with Successful Transplantation

Miceal Cole¹, Ashley Meenagh¹, Tanya Shovlin¹, Bernie Magee¹, Aisling Courtney², Mahendra Mishra¹, Jeanie
Martin¹
1 H& I Laboratory, Belfast City Hospital, Belfast, UK
2 Renal Unit, Belfast City Hospital, Belfast, UK

Background It is commonly accepted that an MFI of > 3000 with the Luminex SAB assay is likely to be
associated with a positive flow crossmatch. We present two successful renal allograft recipients that
showed a deviation from this dictum.

Case 1 A 50 year old lady with history of three pregnancies was being worked up with her spouse as possible
donor. She had a CRF of 56% and her HLA Class II mismatches included DR7, DR9, DQ9, DR53, DP2 and DQ2.
She had an MFI of 8046 directed against DQ9 for which her husband was homozygous. Cell based CDC and
Flow crossmatch results were negative.

Case 2 A 47 year old lady with a history of five pregnancies with her partner had Class II mismatches for
DR7, DR53, DQ2 and DP4. She had a CRF of 10% with a cumulative DSA MFI of 1060. Despite the weak MFI
results the B cell flow cytometry crossmatch with her partner was positive.

Follow up and Conclusion Both patients were successfully transplanted – the first one from her husband
and the latter from pooled pair scheme and are doing well at a recent follow up. Post-transplant available
data until the last follow-up will be presented. These observations

Page 58 of 84

illustrate that multiple tests are imperative to completely define the antibody profile and discrepancies
can exist between Luminex bead and cell based assays.

P26: UK NEQAS for Histocompatibility and Immunogenetics “Standard Method” for CDC Cross-
Matching

Melanie Bartley¹, Felicity May¹, Deborah Singleton¹, Christopher Darke¹

1 UK NEQAS FOR H& I

For several years UK NEQAS for H&I have highlighted considerable variation in CDCXM methodology used by
laboratories in the UK & Ireland for its ‘Cytotoxic Crossmatching’ Scheme 2A. In 2014, 17.5% (28/160) of
CDCXM tests were excluded from assessment for UK & Ireland participants as tests failing a 75%
positive/negative consensus are not assessed.

We determined if a ‘standard method’ would improve the number of tests reaching consensus. This method,
based on that most commonly used by participants, specified an incubation time of 60 minutes both pre-
and post-complement addition, ambient incubation temperature and a cell:serum ratio of 1µl:1µl.
Complement was not standardised but 15 of the 16 participating laboratories used the same manufacturer’s
material.

This ‘standard method’, was evaluated in parallel with six usual Scheme 2A samples (2A03- 2A08/15). 96
cell/serum combinations were analysed [4 sera x 6 donor samples x 2 cell types (B cell+ PBL/T) x 2 (with
DTT/without DTT)].

When laboratories used their own method 15.6% of tests failed to reach consensus compared to 13.5% using
the ‘standard method’ (p=0.7).

For each set of 96 tests the number of laboratories reporting a consensus result with their own method was
compared with their ‘standard method’s’ result. The consensus percentage remained unchanged in 51% of
tests, improved in 22.9% and reduced in 26.0%.

Thus, ‘standardisation’ of the Scheme 2A CDCXM method did not significantly improve consensus results.
Clearly, eliminating variation between laboratories cannot solely be resolved using a ‘standard method’
as many other factors contribute to variation between
Laboratories.

P27: UK NEQAS for H&I's Educational Scheme Incorporating Crossmatching, HLA Typing and
Antibody Detection/Specification

Felicity May¹, Tracey Rees¹, Deborah Singleton¹, Christopher Darke¹

1 UK NEQAS for H&I

UK NEQAS for H&I schemes aim to reflect current clinical practice. Laboratories are often required to interpret
results from multiple assays in order to make clinical decisions. Consequently, an educational exercise was
trialled in which participants reported the results of HLA typing, crossmatching and HLA antibody
detection/specification. They also provided an interpretation of the results as if they were obtained in a
kidney transplant setting. Results were not formally assessed. A total of 20 labs participated although not
all reported on every aspect. Participants were issued with one blood sample and three serum samples.

Page 59 of 84

Serum 1 came from pooled female, non-transfused, blood group AB, blood donors. 12/20 (60.0%) labs
detected donor specific antibodies (DSAs), however 13/14 (92.9%) reported negative T and B cell CDCXM
and FCXM. 14/20 (70.0%) labs classed this as ‘low risk’. Serum 2 came from a highly sensitised, multiparous
female. 20/20 labs detected DSAs. 14/14 reported positive FCXM, 15/16 (93.8%) reported positive CDCXM
without DTT, and 11/14 (78.6%) reported positive CDCXM with DTT. 19/20 (95.0%) labs judged their findings
as a contraindication to transplantation.
Serum 3 came from a ‘moderately’ sensitised female blood donor. 19/19 labs detected DSAs. 8/12 (66.7%)
reported positive T cell FCXM, 14/16 (87.5%) reported negative CDCXM without DTT, and 14/14 labs
reported negative CDCXM with DTT. 12/20 (60.0%) participants classed this as ‘medium risk’.
This exercise has highlighted both concordances but also important variations between different laboratories.
The scheme will be continued and may form the basis of future formal EQA scheme design.

P28: Immunophenotyping as a Profiling Tool in HLAi Renal Transplantation
Katherine Mounsey¹, Clive Carter¹, Nicola Woodroofe², Brendan Clark¹

1 Leeds Teaching Hospitals NHS Trust, Sheffield, UK

Antibody incompatible transplantation represents a key strategy for improving access for sensitised patients
to the preferable treatment of transplantation, for end-stage renal failure. This observational study
investigated key populations of recipient lymphocytes present at various stages of the HLAi transplant
procedure, and assessed the data obtained in combination with other pertinent laboratory and clinical
information. Blood samples provided by seven prospective and thirteen retrospective HLAi kidney transplant
recipients, and nine normal control individuals were analysed. Flow cytometry was utilised to examine
lymphocyte subsets, and to perform T and B cell immunophenotyping. HLA-specific antibody definition was
carried out using a single antigen bead-based assay, employing Luminex technology. The effects of
preconditioning and the immunosuppression received were evident in the lymphocyte subset results of both
groups of patients. Pre-treatment results in the prospective cohort also confirmed a chronic renal failure
effect of reduced cell counts. Both groups of participants showed increased populations of memory T cells
following transplantation, suggesting reconstitution from within this compartment. A peak in HLA-DR
expression on T cells, at six months post-transplantation, was noted in the prospective group. Conversely,
memory B cells remained depressed in both cohorts, with the repopulating B cells demonstrating a
transitional or mature B cell phenotype in the prospective participants. The results demonstrated some
intriguing trends that are worthy of further investigation, and it is recommended that elements of this pilot
study are extended into larger prospective studies.

Page 60 of 84

P29: Unexpected HLA-Bw6 Expression Detected in a Renal Registration Patient
Rachel Wilson¹, Corinna Freeman², Ambika Camille², Ruhena Sergeant², Paul Brookes²
1 Imperial College Healthcare NHS Trust, London, UK
2 Hammersmith Hospital, London, UK
HLA typing samples were received for a renal patient to enable registration on to the ODT Deceased Donor
transplant waiting list. Testing was performed as per the local policy, with initial testing by PCR-SSO (One
Lambda) and confirmatory testing by PCR-SSP using in house primers. Initial typing results for the HLA-B
locus were HLA-B*13 and HLA-B*47, both of which are known to be associated with HLA-Bw4. However
confirmatory testing showed an unexpected amplification of the HLA-Bw6 specific primer. The sample was
sequenced and found to be HLA-B*47:03 which has been confirmed to be associated with HLA-Bw6 rather
than HLA-Bw4. This case highlights a few issues within solid organ transplant setting: 1. Assuming an
HLA-Bw4/Bw6 type based on association rather than testing. 2. Registering patients with an ‘incompatible’
HLA-Bw4/6 type on the ODT Deceased Donor transplant waiting list. 3. The clinical implications in the
deceased donor HLA typing setting.

Page 61 of 84

Author Index

A Wiebke - O4
Abels, Amr - P10
Abid, Ben - O9
ADAMS, Waseem - P24
Alvi-Ali, Arthi - P13
Anand,

B

Bade-Doeding,Christina - O4
- P14
Barnardo, Martin - P26
- O8, O12
Bartley, Melanie - O4
- O11, P9
Battle, Richard - P17
- O1, O6, O7
Blasczyk, Rainer - P12
- P7, P24
Boix, Francisco - P29
- P16
Boswijk, Kim - O1, O6, O7
- P13
Bradbury, Lisa - O14
- P2, P3
Bradley, John - O5

Briggs, David

Brookes, Paul

Brooks, Shannon

Brown, Chloe

Brown, Colin

Bultitude, Will P

Burrows, E

Butler, Andrew

C Ambika - P29
Camille, Bryan Sean - O2, O3, P17
Carey, Clive - P28
Carter, Mian - P14
Chen, Brendan - P8, P28
Clark, Timothy - P20
Climer, Miceal - P25
Cole, Andrew - O2, O3
Connor, Aisling - P23, P25
Courtney,

D

Dalvi, Salmaan - P10
- P2, P3, P4, P20, P21, P22, P26, P27
Darke, Chris - P13
- P20, P22
Davey , Sue - P16

Davies, Elaine

Diaz-Burlinson,Natalia

E F - P2
Edwards, Irina - P3
Evseeva,

Page 62 of 84

F Damian - P5
Finnegan,
Luke - P7, P24
Foster , Finnuala - P9
Fowles, Corinna - P29
Freeman, Susan - O1, O6, O7, P14
Fuggle,

G Jennifer - P15
Gauss, Maria - P8
Gilleece, Petra - P1
Goldsmith, Susana - P6
Gomez, Reetinder - O11
Grewal, Cristina - P19
Guijarro,

H

Hammad, Abdul - P1
- P21, P22
Harvey, Chris - P10
- P15
Harvie, Jordan - O8, O12
- P1
Hemmatpour, Shahram - P11

Henderson, Lorna

Howse, Matthew

Hughes, Chris

I Diane - P15
Irving, Catherine - P8
Irwin, Peter - P8
Irwin,

J Robinson - P19
James , Steven - P16
Jervis, Shirley - P7
Jobson, Jayne - P21
Johnson,

K Leigh - P18
Keen, Thahminna - P15
Khan, - P12
- P12
Knighton, Graham - O4
- P13
Kosmoliaptsis, Vasilis

Kunze-Schumacher,Heike
Kyriacou, Monica

L Katy - O1, P9, P19
Latham, Helena - O9, O10, P11
Lee, Gayle - P19
Leen,

Page 63 of 84

Lemin, Andrew - P7
Lepore, Davide - O11
Logan, Alison - O9, O10
Lowe, David - P1
Lucas, Geoffrey - P18

M

Mabrok, Mazen - P17

Madrigal, J. Alejandro - O13, O14, P6, P19

Magee, Bernie - P25
- P12
Mallon, Dermot - O4

Manandhar, Trishna

Marsden, Neil - P8
Marsh, Steven G. E. - O13, O14, P19

Martin, Jeanie - P5, P23, P25
Martin, Jess - P12

Mathers, Simon - O10, P11
May, Felicity - P4, P26, P27
Mayor, Neema P - O12, O14, P19

McCappin, Jessica - P5
McCaughan, Jennifer - O8

McDermott, Michael - P5
McIlhatton, Brian - P5

McIntyre, Sophie - O12

McWhinnie, Alasdair JM - O13

Meenagh , Ashley - P23, P25

Middleton, Derek - P1
Millington, Rona - P7

Mishra, Mahendra - P23, P25
Mounsey, Katherine - P28

N Olga - P6
Ailish - O12
Nikolajeva,
Nimmo,

P Sarah - O5 , P12
Susan - P5
Peacock, Anthony - O2, O3, P17, P18
Piggott, Kay - O9, P16
Poles,
Poulton,

R Mohammad Ali - P14

Rafique, Laila - P6
Ramzi,
Rana, Bindu - P2, P3
Rawson,
Rees, Jennifer - P24
Rees,
Ridgway, M T - P2, P3

Tracey - P4, P27

Dan - P1

Page 64 of 84

Rizvi, Jasmine - P13
Robertson,Victoria - P10
Robinson, James - O13, P19
Robson, Amanda - O9
Rowe, Peter - O2, O3
Rowlston, Sophia - P11

S

Sage, Deborah - P15
Muhammad, Saif - O9
Salem, Husein - P10
Sergeant, Ruhena - P29
Sharkey, Lisa - O5
Shelper, Linda - O1, O7
Shovlin, Tanya - P23, P25
Singleton, Deborah - P4, P26, P27
Stein, Jeremy E. - P19
Street, Jane - P20, P21, P22

T

Tavarozzi, Franco - O11, P9
Taylor, Craig - P12
Tholoui, Eleni - O9
Thomas, Zoe - P24
Turner, David - O1, O6, O7, O8
Turner, Thomas - O13

W

Wallis-Jones, Shem - O11
Wilson, Rachel - P29
Woodroofe, Nicola - P28
Wroe, Elizabeth - P18
Wynn, Rob - O10

Page 65 of 84

BSHI Annual General Meeting Agenda

Wednesday 14th September 2016 - 11:50 - 13:00
27th BSHI Conference Oxford 2016

Members of the BSHI Committee:

Chair Kay Poulton

Secretary David Turner

Secretary Elect Deborah Pritchard

Treasurer John Smith

Meetings Secretary Katy Derbyshire

Membership Secretary Anna Barker

Chair PAG Brendan Clark

Chair BEB Deborah Sage

Ordinary Member Tom Brown

Ordinary Member James Robinson

Ordinary Member Elizabeth Wroe

Agenda

1. Apologies from Committee Members
2. Matters arising from previous meeting on 10th September 2015
3. Chair’s Report
4. Secretary’s Report
5. Treasurer’s Report
6. Membership Secretary’s Report
7. Meetings Secretary’s Report
8. BSHI Education Board Report
9. Professional Advisory Group Report
10. Any other business

Page 66 of 84

TOILETS 78 ROSE SAVANT LTD IMMUCOR Exhibition Floor Plans

CORRIDOR TO 69 ALPHA BIO
TOILETS TECH

Page 67 of 84 3 4 5 LINKAGE BIO MC 10
STEMCELL VH BIO DIAGNOSTICS 11
2
PROMEGA GENDX
1
Window
Windows
ILLUMINA Delegates enter Arco via Fire
Exit doors

Milentyi Biotech and Agilent Technologies are exhibiting in the Poster Room in the
Sloane Robinson Building. Please ensure you take time to visit these stands as well

Exhibiting Companies

Agilent Technologies – Poster Room Stand 2

Dako was established in and has played a pioneering role in the standardizing antibodies for clinical use, since
then the company has grown into a global business with a leading position in the in vitro diagnostics industry.
Dako has manufacturing and research sites in Denmark and the United States. Dako's manufacturing facilities
have established quality management systems designed to live up to the most stringent standards in the in
vitro diagnostics industry.

In 2012, Dako became part of Agilent Technologies –the world’s premier measurement company. Agilent has
a global footprint of more than 10, 000 with an established global reach that is now benefitting Dako. Dako’s
comprehensive product portfolio in Specific Proteins and Flow Cytometry supported by a world-wide network
of distributors ensures prompt access and support to partners and customers around the globe.

Dako has an extensive range of antibody and isotype reagents for flow cytometry of which more than 200
are CE-IVD labeled. Our single-color, dual-color and triple-color reagents are applicable to major flow
cytometry instruments and are the carefully selected combinations of antibodies and fluorochromes.

Alpha Biotech Ltd – Stand 6

Come and talk to us about a whole range of products from our specialist suppliers of HLA typing kits,
equipment and consumables.

ART ROBBINS INSTRUMENTS – Our long established association with the many innovative products for
serological and molecular HLA typing continues with this company. Newly manufactured Autoscope stages
as well as fully reconditioned Serum Dispensers and Plate Oilers. Single and Multi Syringe Dispensers,
Complement Cups and Serum Tubes. The Cobra non-contact dispenser, used for on the fly dispensing into
96, 384 and 1536 PCR trays, will also dispense cells into HLA typing trays.

OLERUP SSP – The most complete and up to date range of high and low resolution SSP typing kits with
SCORETM analysis software.

OLERUP QTYPE – The first commercial release of QTYPE is released September 2016 allowing 11 loci typing
in 60 minutes. QTYPE uses 4 hydrolysis probes per well allowing for multiplexing and expansion of typing
resolution as the number of alleles discovered increases.

OLERUP – CONEXIO SBT RESOLVER - Olerup has worldwide marketing and distribution rights for SBT
Resolver and Assign TM SBTv471 which includes analysis of non-coding regions and also GSA analysis. SBT
Resolver uses single tube Locus specific PCR based HLA sequencing based typing products. A comprehensive
range of HARPS ® is available for all HLA loci.

QIAGEN – EZ1 – CE/IVD robotic extraction of DNA from blood and other tissues.

Page 68 of 84

ALPHA HELIX – α‑Bot - Robust and compact robotic workstation.
Contact: Robert Cordingley Email: [email protected] Web: www.alphabiotech.co.uk

GenDx – Stand 11 and Lunchtime Workshop

The HLA Sequencing Experts

Expertise in workflows for HLA typing and sequencing data analysis characterise GenDx as innovator and
market leader in the HLA typing field. Developing new solutions and offering excellent support and education
to HLA labs are our primary objectives. Find out more about products and services:

· NGSgo® & NGSengine®

· SBTexcellerator®, GenDx-AlleleSEQR® & SBTengine®

· qPCR Chimerism monitoring with KMRengine®

For more info contact our Technical Support Team:

www.gendx.com phone: +31 30 252 3799 [email protected]

Gendx Lunchtime Workshop: HLA Typing always the Next level. - Wednesday 13:50 - Music Room

During this workshop we will show how different NGS platforms can suit your needs in a multicentre
platform comparison and which factors will make the implementation of Next Generation Sequencing
successful in your HLA lab.

If you would like to take Chimerism Monitoring to the next level as well, the introduction of our qPCR solution
will suit your ambitions. Join this second part to find out how KMRtype, KMRtrack and KMRengine can
increase your sensitivity over 20x and simplify your laboratory workflow.

Illumina – Stand 1 and Lunchtime Workshop

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic
variation and function, making studies possible that were not even imaginable just a few years ago.

With such rapid advances in technology taking place, it is mission critical to have solutions that are not only
innovative, but flexible, scalable, and complete with industry-leading support and service. Illumina’s
innovative, Array and Next Generation Sequencing based solutions for DNA, RNA, and protein analysis
serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Page 69 of 84

Human leukocyte antigen (HLA) plays a significant role in the ability of the immune systems to recognise
invasive, foreign, infected and malfunctioning cells. The immune system efficiently removes such cells to
fight disease and main overall health. HLA mutations can produce aberrant immune response and have been
associated with autoimmune disorders, cancer, transplant rejection, and drug sensitively

For further details please visit www.illumina.com.

Illumina Workshop - Wednesday 13:30 - Seminar Room 1

Immucor – Stand 9

Founded in 1982, Immucor is a global leader of transfusion and transplantation diagnostics. Our LIFECODES
line offers HLA donor-patient compatibility for solid organ transplants, as well as Donor Specific Antigen and
C3d monitoring for post-transplant success. Our NGS based MIA FORA assay raises the bar for bone marrow
HLA compatibility testing and kSORT is a novel, non-invasive approach to assessing potential kidney graft
failure.

Linkage BioSciences – Stand 5

Linkage Biosciences™ is a molecular diagnostics company developing and marketing products that dramatically
improve and expedite complex genetic testing. LinkSēq™ is the company’s Human Leukocyte Antigen (HLA)
testing product line. The company is headquartered in South San Francisco, California, USA, with a regional
office in Geneva, Switzerland

MC Diagnostics Ltd – Stand 10 and Lunchtime Workshop

Automated HLA typing and Antibody Detection

The HISTO SPOT ® SSO System provides a simple, rapid, fully automated process for HLA typing and HLA
Antibody Screening & Identification.

MC Diagnostics Lunchtime Workshop - Tuesday 12:45 - Seminar Room 2

Join our lunch time workshop to find out more information on the new antibody detection product, Tuesday
13th Sept 12:45 Seminar Room 2.

Milentyi Biotec – Poster Room Stand 1

Omixon – Lunchtime workshop

Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in
Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s
flagship product, Holotype HLA™, is the world’s leading NGS- based HLA genotyping product that delivers
the most accurate high-resolution HLA genotyping available, and is used in more than 20 hospitals worldwide.
Omixon’s research software, HLA Explore™ analyzes data from any sequencing technology and determines
HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active

Page 70 of 84

grant-funded research program with a product pipeline focused on pre- and post- transplantation,
and HLA genotyping applications beyond transplantation.

Omixon Lunchtime Workshop - Wednesday 13:50 - Seminar Room 2
News and improvements - CEO Tim Hague and Director of Sales Marcello Scala will announce major
improvements to the exiting products.

Promega UK Ltd – Stand 2

With a portfolio of more than 3,000 products in genomics, protein analysis and expression, cellular analysis,
drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical
support to life scientists in academic, clinical, industrial and government laboratories.
Promega products are used by researchers who are asking fundamental questions about biological
processes as well as by scientists applying scientific knowledge to diagnose and treat diseases, discover
new therapeutics, and use genetics and DNA testing for human identification.
Promega holds significant intellectual property rights and licenses in several key areas that form a
foundation for its diverse portfolio.

ROSE Gentec – Stand 7

R.O.S.E. GenTec Ltd., UK Branch of the R.O.S.E. International Group, is one of the leading companies in the
world that dedicates itself to the development, manufacture and marketing of high quality and cost-efficient
in-vitro diagnostic products and services. We offer high quality HLA SBT Typing Kits and HLA SSP Typing Kits
to analyze the human leukocyte antigens for the tissue typing process.
We implemented a high quality management system according to ISO 9001, ISO 13485 and Directive
98/79/EC for medical device manufacturer. R.O.S.E. International Group sincerely welcomes business
partnerships and research collaborations worldwide. If you are interested in working with us, do not hesitate
to contact our staff.

Savant Limited – Stand 8

Hematos IIG is designed for use by specialist blood, tissue and stem cell testing and typing organisations to
support histocompatibility and immunogenetics, together with cellular and molecular therapies. It is a highly
flexible, configurable system which can record any immuno‐genetic test data including HLA and HPA types.
Hematos IIG incorporates a quick and efficient advanced matching routine that not only matches donor
HLA  tissue  types  to  recipient,  but  also  is  able  to  record  close  matches  and  search  profiles.  It  ensures  a
secure environment, it is user-friendly, saves time and reduces the risk of human error.

Page 71 of 84

At Savant we pride ourselves on the flexibility of all our systems and Hematos is no exception. It is flexible
and  highly  configurable  to  meet  specific  customer  requirements.  For  example,  with  the  National  Health
Service Blood and Transplant, we have helped design, load and validate over ten thousand system settings
to enable them to carry out vital blood and tissue testing, cross matching, bacteriology and ante-natal work.

Other key features include: -

• Task management system to manage patient/donor events and reminders

• Configurable search engine and reporting

• One or two way automated import of results

• Ability to exchange data with other databases

• A world-wide user base

• Multi-lingual – Hematos IIG can manage data and report in many languages

To know more about Hematos IIG, please contact us at Savant on 01524 784400.

Stemcell Technologies – Stand 3

STEMCELL Technologies Inc. is committed to providing specaialized cell isolation products, standardized
cell culture media and accessory tools for your hematology and cell therapy research. Driven by science
and a passion for quality, STEMCELL delivers more than 2000 products to over 80 countries worldwide.
To learn more, visit stemcell.com.

Takara – Lanyard sponsor

Through our brand names TAKARA®, CLONTECH® and CELLARTIST we develop innovative technologies in
the fields of Cell Biology, Molecular Biology, Proteomics and Stem Cell Research. From next-generation
sequencing and PCR, to cloning and genomics, we offer high- performance reagents you can count on for
all areas of molecular biology.
Key products include high performance PCR/qPCR for HLA NGS typing, SMARTerT cDNA synthesis kits for
Next Generation Sequencing, innovative In-Fusion® HD Cloning Plus System, Tet-regulated gene expression
systems, Living Colors® Fluorescent Proteins, as well as a broad choice of viral vectors/particles and
transduction tools. With the recent acquisition of Takara Bio Europe AB (formerly Cellartis), Takara Bio has
expanded its portfolio with ready-to-use hiPSC derived hepatocytes and cardiomyocytes, culture media, as
well as services such as iPS cell generation, engineering and differentiation.
Our best-in-class products are backed by expert technical assistance, because we believe good science needs
great support.

Page 72 of 84

VH Bio Ltd – Stand 4 and Lunchtime Workshop

VH Bio Ltd is a leading supply and distribution company for the life sciences industry within the United
Kingdom and Republic of Ireland with novel and innovative products sourced from our global partners. VH
Bio is the preferred choice for transplant diagnostics, molecular biology, cell biology and Immunology.
We will be focusing the stand on new technologies and products released from One Lambda.
The New products include:
SmartType™ the new QPCR product released by One Lambda, designed to run on a number of real time PCR
instruments such as the QuantStudio DX.
NXType™ One Lambda’s Next Generation Typing reagents designed for the torrent based sequencing
systems, reagents available for both PGM and the S5.
Please enquire about the continuous enhancements to the more well-established product groups such
as:
LABType™, CWD and XR kits now part of this product group designed for the LABScan 3D™ instrument.
SeCore™ SBT Class I kits contain additional primers for A (exons 1 and 5), B (exons 1 and 5) and C (exons 1,
5, 6 and 7) and are designed to target and resolve CWD alleles, including null alleles within assigned G groups.
LABScreen® Multi kit now part of this product group which is capable of detecting HLA Class I and II and
HNA 1a, 1b, 1c, 2, 3a, 3b, 4a, 5a, and 5b antibodies.
Please visit the VH Bio Ltd stand (4) to collect your BSHI mug and have a chance of winning £100 in Amazon
vouchers playing ‘Spin the wheel with Soulsby’!
VH Bio Lunchtime Workshop - Tuesday 13:15 - Seminar Room 1
VH Bio’s Lunch Symposium is presented by Sean Carey from Derriford Hospital, Plymouth Hospitals NHS
Trust. Sean will be talking about his experience with One Lambda’s NXType HLA NGS Typing kit.

Page 73 of 84

Delegate List

Surnam e First Name Institution

Adams Ben Central Manchester Foundation Trust (CMFT)

Agudelo Juliet Oxford Transplant Centre

Aitchison Katherine Anthony Nolan

Akbarzad-Yousefi Arash Anthony Nolan

Barker Daniel NHSBT Filton

Barker Anna Central Manchester Foundation Trust (CMFT)

Barnardo Martin Oxford Transplant Centre

Bartley Melanie UK NEQAS for H&I

Blow Sarah Hammersmith Hospital

Bloxham Maureen Transplant Laboratory Leicester General Hospital

Bradbury Lisa NHS Blood and Transplant

Briggs David NHSBT

Brookes Paul Imperial College NHS Trust

Brookes (Nee Price) Jessica North Bristol NHS Trust

Brooks Shannon Central Manchester Foundation Trust (CMFT)

Brown Colin NHS Blood and Transplant

Bultitute Will Anthony Nolan

Caddick Jonathan NHS Blood and Transplant

Camille Ambika Hammersmith Hospital

Carey Sean Derriford Hospital

Carter Douglas Vaughan NHS Blood and Transplant

Chen Mian Oxford Transplant Centre

Chisman Ruth NHS Blood and Transplant

Clark Brendan Leeds Teaching Hospitals

Cole Miceal H&I lab Belfast City Hospital

Cook Emma WTAIL

Cutland Gemma Oxford Transplant Centre

Davey Sue NHSBT

Davis Paige BSHI Secretariat

Day Sarinder North Bristol NHS Trust

Delavalle Penelope NHSBT

Diaz Burlinson Natalia Central Manchester Foundation Trust (CMFT)

Easton Jennifer Oxford Transplant Centre

Edwards Sara Addenbrookes

Evseeva Irina Anthony Nolan

Foster Luke NHS Blood and Transplant, Birmingham

Fower Dan Oxford Transplant Centre

Fowles Finnuala Anthony Nolan

Fuggle Susan Oxford Transplant Centre

Gardiner Michelle Beaumont Hospital

Grant Joyce Royal Free Hospital

Haeger Ash Oxford Transplant Centre

Hague Tim Omixon

Halford Emily NHS Blood and Transplant

Hancocks Emma Anthony Nolan

Page 74 of 84

Hanson Vivien Anthony Nolan
Harmer Andrea NHS Blood & Transplant
Hassall Kylara Anthony Nolan
Hathaway Mark NHS Blood and Transplant
Higgins Alice BSHI Secretariat
Hughes Chris Central Manchester Foundation Trust (CMFT)
Hughes Pamela Leeds Teaching Hospital
Irwin Catherine Leeds Teaching Hospitals
Jameson Jamie Oxford Transplant Centre
Kane Julie Central Manchester Foundation Trust (CMFT)
Kelly Joseph Beaumont Hospital
Kenworthy Hannah Oxford Transplant Centre
Khalib Khairin Beaumont Hospital, Dublin
Latham Katy Anthony Nolan
Lenehan Claire Beaumont Hospital
Lepore Davide Anthony Nolan
Lin Li H&I, SNBTS, Royal Infirmary of Edinburgh
Mabrok Mazen Derriford Hospital - Plymouth
Manandhar Trishna Institute of Transfusion Medicine, Hannover Medical School
Marsh Steven Anthony Nolan Research Institute
Martin Jeanie Belfast Health & Social Care Trust
Mathers Simon Central Manchester Foundation Trust (CMFT)
May Felicity WTAIL
Mccaughan Jennifer Glasgow
Mcilhatton Brian Belfast Health & Social Care Trust
Mckenzie David Gartnavel General Hospital
Mishra Mahendra Belfast City Hospital
Nicol Louise H&I, SNBTS, Royal Infirmary of Edinburgh
Nimmo Ailish Royal Infirmary of Edinburgh
Nneke Obiajulu Royal Brompton and Harefield Hospital
Peacock Sarah Addenbrookes Hospital
Poles Anthony NHS Blood & Transplant
Poulton Kay Central Manchester Foundation Trust (CMFT)
Pritchard Deborah UK NEQAS for H & I
Rendel Sandrine QUOD Biobank
Robertson Victoria PCG
Robinson James Anthony Nolan
Robson Amanda Central Manchester Foundation Trust (CMFT)
Rodgers Angela Gartnavel Tissue Typing
Rowe Emma NHSBT
Sacco Precious NHSBT
Sage Deborah NHSBT-TOOTING CENTRE
Sanichar Maryna Sheffield H&I
Sansom Helen Oxford Transplant Centre
Scala Marcello Omixon
Shelper Linda NHS Blood and Transplant
Singh Rena Immucor
Smith John Royal Brompton & Harefield
Sunkur Pounum NHSBT COLINDALE

Page 75 of 84

Sutton Maggie Oxford Transplant Centre
Trujillo Cristabel Anthony Nolan
Turner David Scottish National Blood Transfusion Service
Turner Thomas Anthony Nolan
Udoffia Ufot Anthony Nolan
Walsh Louise Beaumont Hospital
Weston Stephen Leicester General Hospital
Wilson Rachel Imperial College Healthcare NHS Trust
Wood Victoria Leeds Teaching Hospitals NHS Trust
Wright Paul Central Manchester Foundation Trust (CMFT)

Page 76 of 84

Notes

Page 77 of 84

Notes

Page 78 of 84

Notes

Page 79 of 84

Notes

Page 80 of 84

Notes

Page 81 of 84

Notes

Page 82 of 84

NXType™

NEXT GENERATION SEQUENCING ASSAYS

MOVING HLA TYPING INTO THE FUTURE

1984

2016

Speed • Simplicity • Scalability • Software •
Support

One Lambda’s complete NGS solution just got easier with the introduction of the
NXType™ Assay on the Ion S5™ System. NXType™ reagents feature a unique
multiplex amplification design that reduces library preparation to less than 10 hours.
Our new Ion S5 and S5 XL Systems feature cartridge based reagents while
providing sample flexibility for laboratories of all sizes. With sequencing run times
under 6 hours, and automated HLA genotyping using HLA TypeStream™,
our rapid sample­to­results NGS workflow can be completed in less than 3 days.

To learn more contact VH Bio’s product specialists on 0191 495 8210